Market Trends of Global Protein A Resin Industry
Pharmaceutical and Biopharmaceutical Companies are Expected to Dominate the End User Segment
Pharmaceutical and biopharmaceutical companies mainly use proteins as the principal target, and thus, protein analysis has a very important role in drug discovery and development in the pharma and biotech industries. The common application of protein analysis involves target identification, evaluation, identification of efficacy and toxicity biomarkers from readily accessible biological fluids, and investigations into mechanisms of drug action or toxicity, among others, which in turn is expected to grow significantly due to a large number of ongoing drug development projects in the pharmaceutical and biopharmaceutical projects across the world.
A rise in government funding for pharmaceutical research and development and technological advancements in the area of analytical instruments are expected to drive the growth of the studied segment. Also, increasing life science R&D expenditure, progressing drug discovery, and an increase in the adoption of chromatography are key factors driving the growth of the protein A resins market in the pharmaceutical and biopharmaceutical industries. For instance, the data published by EFPIA in 2022 mentioned that the research and development expenditure of the pharmaceutical industry in Europe in 2021 was EUR 41.5 million (USD 44.6 million). Such high pharmaceutical expenditures are expected to drive the demand for protein A resin in drug development research and the development of various diagnostic tests, thereby boosting the growth of the studied segment.
Additionally, increasing product launches in order to address the demand from the pharmaceutical and biopharmaceutical industries are also expected to contribute to the growth of the market. For instance, in September 2021, Purolite launched two novel next-generation chromatography resins, Praesto Jetted A50 HipH, and Praesto Jetted dt 18-DVD to address the diversity of biomolecule pipelines of antibodies, vaccines, and gene therapy.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The market for protein A resin in the North American region is expected to experience lucrative growth owing to the factors such as the rising burden of infectious and chronic diseases, technological advancements in the studied market, and increasing research and development expenditure on pharmaceutical and biological research. In addition, the product launches and strategic initiatives by key market players will also contribute to the market growth.
For instance, according to the American Cancer Society Inc., data published in 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. In addition, according to the Public Health Agency of Canada data published in October 2021, approximately 2 in 5 Canadians were diagnosed with cancer in their lifetime, and in 2021, an estimated 229,000 Canadians were diagnosed with cancer. The report also mentioned that lung, breast, colorectal, and prostate cancers were expected to remain the most commonly diagnosed cancers, accounting for nearly 46% of all cancer diagnoses in 2021. Such a high prevalence of chronic diseases in North American countries is expected to contribute to the demand for protein A resin for diagnostic purposes and the development of appropriate therapies, thereby boosting the market growth.
On the other hand, the rising product launches by various market players to meet the growing demand for protein A resin is also expected to fuel the market growth in this region. For instance, in March 2022, Sengenics launched an autoantibody profiling service - the 'Pan-Autoimmune Protein Array 1.0' for efficient identification and quantitation of autoantibody disease biomarker signatures. It is a protein microarray-based, multiplexed immunoassay which utilizes Sengenics' KREX protein folding technology and optimized computational analysis.
